CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial-Reference-Cited by-同舟云学术

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

Published:2012-03-06 Issue:6 Volume:104 Page:441-451
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Regan Meredith M.,Leyland-Jones Brian,Bouzyk Mark,Pagani Olivia,Tang Weining,Kammler Roswitha,Dell’Orto Patrizia,Biasi Maria Olivia,Thürlimann Beat,Lyng Maria B.,Ditzel Henrik J.,Neven Patrick,Debled Marc,Maibach Rudolf,Price Karen N.,Gelber Richard D.,Coates Alan S.,Goldhirsch Aron,Rae James M.,Viale Giuseppe

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/104/6/441/17312210/djs125.pdf

Reference35 articles.

1. Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists’ Collaborative Group (EBCTCG);Lancet.,2005

2. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer;The Breast International Group (BIG) 1-98 Collaborative Group;N Engl J Med.,2005

3. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98;Coates;J Clin Oncol.,2007

4. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer;The Breast International Group (BIG) 1-98 Collaborative Group;N Engl J Med.,2009

5. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study;Colleoni;J Clin Oncol.,2011

Cited by 298 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Solanidine Metabolites as Diet‐Derived Biomarkers of CYP2D6‐Mediated Tamoxifen Metabolism in Breast Cancer Patients;Clinical Pharmacology & Therapeutics;2024-07-22

2. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-07

3. Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort;Clinical Pharmacology & Therapeutics;2024-03-18

4. Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data;Clinical and Translational Science;2024-03

5. Germline pharmacogenomics in cancer treatment;Diagnostic Molecular Pathology;2024